Abiraterone acetate in advanced prostate cancer

As many of you know, Sally Church attended the recent European Association of Urology Congress in Vienna.

In the first video blog post that she’s ever done on Pharma Strategy Blog, she shares her impressions of the meeting and the changing landscape in advanced prostate cancer.  One of the key new product approvals expected this year is for abiraterone.

We love the “BBC News” style graphics of her video blog, and look forward to hearing from Sally throughout the course of the year as she attends other conferences.

You can now watch Sally on her own YouTube channel.  Will we see “Sally Church reporting live for Pharma Strategy Blog”?

, , , , , , , , , , , , , , , , , , , , ,

error: Content is protected !!